1364 related articles for article (PubMed ID: 7856434)
1. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
Falsetti L; Pasinetti E
Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
Falsetti L; Galbignani E
Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
[TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone.
Akerlund M; Almström E; Högstedt S; Nabrink M
Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352
[TBL] [Abstract][Full Text] [Related]
4. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
[TBL] [Abstract][Full Text] [Related]
5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
6. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.
Mastorakos G; Koliopoulos C; Creatsas G
Fertil Steril; 2002 May; 77(5):919-27. PubMed ID: 12009344
[TBL] [Abstract][Full Text] [Related]
7. Clinical and metabolic study of a new pill containing 20 mcg ethinylestradiol plus 0.150 mg desogestrel.
Fioretti P; Fruzzetti F; Navalesi R; Ricci C; Miccoli R; Cerri M; Orlandi MC; Melis GB
Contraception; 1987 Mar; 35(3):229-43. PubMed ID: 2956055
[TBL] [Abstract][Full Text] [Related]
8. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma viscosity in young women with polycystic ovary syndrome using an oral contraceptive containing 35 μg ethinyl estradiol and 2 mg cyproterone acetate.
Markantes G; Saltamavros AD; Vervita V; Armeni AK; Karela A; Adonakis G; Decavalas G; Georgopoulos NA
Gynecol Endocrinol; 2011 Dec; 27(12):971-7. PubMed ID: 21501001
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
Porcile A; Gallardo E
Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
[TBL] [Abstract][Full Text] [Related]
11. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R
Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546
[TBL] [Abstract][Full Text] [Related]
12. Lipid metabolic studies in women with a polycystic ovary syndrome during treatment with a low-dose desogestrel-ethinylestradiol combination.
Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G
Acta Obstet Gynecol Scand; 1985; 64(3):203-7. PubMed ID: 3160212
[TBL] [Abstract][Full Text] [Related]
13. Increased follistatin levels after oral contraceptive treatment in obese and non-obese women with polycystic ovary syndrome.
Chen MJ; Yang WS; Chen HF; Kuo JJ; Ho HN; Yang YS; Chen SU
Hum Reprod; 2010 Mar; 25(3):779-85. PubMed ID: 20093255
[TBL] [Abstract][Full Text] [Related]
14. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
Kuhnz W; Staks T; Jütting G
Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
[TBL] [Abstract][Full Text] [Related]
16. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on lipid and carbohydrate metabolism in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Trpković D; Balint-Perić L
Gynecol Endocrinol; 1990 Sep; 4(3):157-68. PubMed ID: 2284980
[TBL] [Abstract][Full Text] [Related]
17. Ethinylestradiol/cyproterone acetate in polycystic ovary syndrome: lipid and carbohydrate changes.
Villaseca P; Hormaza P; Cárdenas I; Oestreicher E; Arteaga E
Eur J Contracept Reprod Health Care; 2004 Sep; 9(3):155-65. PubMed ID: 15697105
[TBL] [Abstract][Full Text] [Related]
18. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives.
Oyelola OO
Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671
[TBL] [Abstract][Full Text] [Related]
19. Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.
Suikkari AM; Tiitinen A; Stenman UH; Seppälä M; Laatikainen T
Fertil Steril; 1991 May; 55(5):895-9. PubMed ID: 1708731
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Effects of a Commonly Used Combined Hormonal Oral Contraceptive in Women With and Without Polycystic Ovary Syndrome.
Adeniji AA; Essah PA; Nestler JE; Cheang KI
J Womens Health (Larchmt); 2016 Jun; 25(6):638-45. PubMed ID: 26871978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
